Q-VANT Biosciences
Stein Løkstad is a seasoned professional in the pharmaceutical and biotechnology sectors, currently serving as Vice President of Business Development at Q-VANT Biosciences since January 2022, where the focus is on innovative supply chain solutions for QS-21 and other Quillaja-based saponin adjuvants. In addition to this role, Stein has been an Executive Advisor at Stein ApS since March 2017, specializing in strategy and business development for global vaccine projects. Previous experience includes key leadership positions such as General Manager at Brenntag Biosector A/S, where responsibilities encompassed vision, strategy, and P&L management, as well as serving as Business Unit Director for Brenntag’s Healthcare division. Stein's extensive career is complemented by advisory roles and contributions to industry committees, including as Chairman of the Life Sciences Committee at FECC. Educational credentials include an International Executive Program at INSEAD, leadership training at Harvard Business School, and a Master’s degree in Political Science from the University of Bergen.
This person is not in any teams
This person is not in any offices
Q-VANT Biosciences
Q-VANT is a privately held company that has solved the supply chain problem of QS-21 and other Quillaja-based saponin adjuvants for the global human and animal pharmaceutical markets. The company’s next-generation technology platform combines computational learning techniques with a proprietary multi-step purification process to increase the supply of QS-21 by more than 1,000 – enabling the production of billions of doses annually to meet today’s increasing global market demand. Led by a team with unrivalled experience in vaccine and adjuvant development, manufacturing and global regulatory requirements, and with world-class knowledge in Quillaja saponin supply chain, agronomy, extraction and purification, Q-VANT is the first company that is vertically integrated to combine a secured sustainable Quillaja raw material supply with pharma cGMP commercial-scale production of QS-21 and other saponin-based adjuvants. For more information, visit www.q-vant.com.